Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04731675 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
A Phase 2 study, sponsored by AmMax Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT04731675 is a Phase 2 study that has completed, run by AmMax Bio. The registered enrollment target is 11 participants.
The verdict
NCT04731675, a Phase 2 study, has completed, sponsored by AmMax Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
AMB-051-01 is a multicenter study with an adaptive design that will enroll subjects with Tenosynovial Giant Cell Tumor (TGCT) of the knee for 12 weeks of multiple-dose, open-label treatment with intra-articular AMB-05X.
Interventions
- BIOLOGICAL AMB-05X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-05-25 |
| Est. Completion | 2022-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04731675
The ClinicalTrials.gov registry entry for NCT04731675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AmMax Bio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMB-05X is the first listed.
NCT04731675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04731675 about?
NCT04731675 is a clinical study titled "An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee". AMB-051-01 is a multicenter study with an adaptive design that will enroll subjects with Tenosynovial Giant Cell Tumor (TGCT) of the knee for 12 weeks of multiple-dose, open-label treatment with intra-articular AMB-05X.
What is the current status of trial NCT04731675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2021-05-25. Estimated completion is 2022-05-05.
What interventions are being tested in trial NCT04731675?
The interventions under investigation include: AMB-05X (BIOLOGICAL).
Who is sponsoring clinical trial NCT04731675?
This trial is sponsored by AmMax Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.